Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. (not Madrigal Pharmaceuticals, Inc., as indicated in the metadata) on February 26, 2007. The filing addresses Item 5.02 regarding compensatory arrangements for Named Executive Officers (NEOs). The report details salary adjustments effective January 1, 2007, and cash bonus awards for performance during the fiscal year ended December 31, 2006.
Key Financial Metrics
The filing does not provide company-wide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- 2007 Annual Base Salaries:
- Safi R. Bahcall (CEO): $355,000
- Keith S. Ehrlich (CFO): $230,000
- James G. Barsoum (SVP, Research): $240,000
- Eric W. Jacobson (CMO): $280,000
- Keizo Koya (SVP, Drug Development): $270,000
- 2006 Cash Bonus Awards:
- Safi R. Bahcall: $100,000
- Keith S. Ehrlich: $44,000
- James G. Barsoum: $46,000
- Eric W. Jacobson: $65,000
- Keizo Koya: $52,000
- Revised Total 2006 Compensation: Ranges from $495,174 (CFO) to $1,065,175 (CEO).
Material Changes
The primary material change is the formal approval and disclosure of executive compensation that was previously pending. The Compensation Committee approved base salary increases effective January 1, 2007, and finalized 2006 performance bonuses. These bonus amounts were excluded from the Summary Compensation Table in the company's Prospectus filed on February 7, 2007, because the amounts had not yet been determined at that time.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of corporate risks and contingencies. The document serves strictly as a supplement to the Summary Compensation Table in the previously filed Prospectus to ensure accurate disclosure of executive pay.
Key Facts for Investor Verification
- Verify the discrepancy between the metadata company name (Madrigal Pharmaceuticals) and the actual registrant (Synta Pharmaceuticals Corp.).
- Confirm that the 2006 bonus awards listed here were not included in the February 7, 2007 Prospectus.
- Note that the CEO's base salary increase was approved on February 28, 2007, while other NEOs' increases were approved on February 26, 2007.
- Review the revised total compensation figures for 2006, which now include the newly disclosed cash bonuses.